University of California, San Francisco

NovApproach Spine Elects Sigurd H. Berven, MD, to Board

Retrieved on: 
Thursday, October 12, 2023
Research, MD, UCSF, University, Stanford University, University of Oxford, Growth, Harvard Medical School, University of California, San Francisco, Surgeon, National Center for Spinal Disorders, Patient, San Francisco, Dentistry, Nursing

ALACHUA, Fla., Oct. 12, 2023 /PRNewswire/ -- NovApproach Spine, developer of the patented OneLIF™ interbody spinal fusion system, which supports a multitude of surgical approaches, announced today the election of orthopaedic surgeon Sigurd Berven, MD, to its board of managers. Berven is the chief of spine service and professor of orthopedic surgery at the University of California, San Francisco (UCSF). A member of NovApproach's OneLIF design team, Berven was the first to use the implant in spine surgery.

Key Points: 
  • ALACHUA, Fla., Oct. 12, 2023 /PRNewswire/ -- NovApproach Spine, developer of the patented OneLIF™ interbody spinal fusion system, which supports a multitude of surgical approaches, announced today the election of orthopaedic surgeon Sigurd Berven, MD, to its board of managers.
  • Berven is the chief of spine service and professor of orthopedic surgery at the University of California, San Francisco (UCSF).
  • A member of NovApproach's OneLIF design team, Berven was the first to use the implant in spine surgery.
  • NovApproach CEO Raymond Cloutier reports, "Dr. Berven has been a chief contributor to the OneLIF cage's evolution.

South Rampart Pharma to Participate in Upcoming Investor Events

Retrieved on: 
Tuesday, October 10, 2023
Shades of gray, BIO, Central nervous system, Liver, UCSF, Clinic, NINDS, University, Biological activity, Therapy, HEAL, Partnership to End Addiction, Mission, DSM-IV codes, Safety, Bangladesh Technical Education Board, Pain, National Institutes of Health, Conference, University of California, San Francisco, Entrepreneurship, NIH, Pharmaceutical industry

NEW ORLEANS, Oct. 10, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company developing SRP-001, a first-in-class non-opioid candidate for the treatment of chronic and acute pain, today announced the Company's executive team will be participating in the upcoming investor events throughout October 2023:

Key Points: 
  • South Rampart's Co-founder and CEO, Dr. Hernan Bazan, will present a Corporate Overview followed by a questions and answers session.
  • Dr. Bazan's presentation will discuss SRP-001's unique mechanisms of action as well as Phase 1 clinical trial data.
  • In addition to the Corporate Overview, Dr. Bazan will be featured as a speaker on a panel exploring best practices for translation and commercialization of innovation spun out from academia.
  • 17th Annual Pain Therapeutics Summit (San Diego, CA):
    Title: "Transcriptomic Signature, Bioactivity and Safety of a Non-hepatoxic Novel Non-opioid Analgesic: From Discovery to the Clinic."

A Quarter Century of Disease-Focused Neuroscience

Retrieved on: 
Tuesday, October 3, 2023
Epilepsy, San Francisco, Huntington's disease, Central nervous system, Therapy, Prevalence, Stanford University, Apolipoprotein, Biogen, Biotechnology, University of California, San Francisco, Brain, Research, DSM-IV codes, Multiple sclerosis, Fairmont San Francisco, AstraZeneca, Eli Lilly, Neuroscience, Amyloid, Parkinson's disease, UC, Myenteric plexus, Patient, Tau, Trustee, SAN, Gladstone Institutes, Spectrum, Blood, Weill Cornell Medicine, Sanofi, BMS, Merck, Takeda Pharmaceutical Company, Disease, Pharmaceutical industry, Vaccine, Nursing, Lundbeck, Alzheimer's disease, Genentech, MD, William Ewart Gladstone

SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- A quarter century ago, in September 1998, Gladstone Institutes launched the Gladstone Institute of Neurological Disease. In 2023, it brought together investigators and alumni to celebrate the institute's 25th anniversary, reflect on landmark scientific achievements, and look ahead at the future of disease-focused neuroscience.

Key Points: 
  • SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- A quarter century ago, in September 1998, Gladstone Institutes launched the Gladstone Institute of Neurological Disease.
  • In 2023, it brought together investigators and alumni to celebrate the institute's 25th anniversary, reflect on landmark scientific achievements, and look ahead at the future of disease-focused neuroscience.
  • As populations around the world are living longer, aging-related neurodegenerative disorders have been rising in prevalence at an unprecedented pace.
  • These landmark discoveries, and many others, were presented on September 15, 2023, as part of the symposium "Disease-Focused Neuroscience: From Discovery to Translation."

LifeSpan Vision Ventures Invests in Deciduous Therapeutics

Retrieved on: 
Tuesday, October 3, 2023
San Francisco, University of California, San Francisco, POC, NKT, Longevity, Notifiable disease, University, Therapy, Natural killer T cell, DSM-IV codes, UCSF, Vaccine

NORWALK, Conn., Oct. 3, 2023 /PRNewswire/ -- LifeSpan Vision Ventures today announced an investment in Deciduous Therapeutics, a pioneering longevity biotechnology company dedicated to enhancing human healthspan by developing innovative medicines targeting the elimination of senescent cells through restoring endogenous immune mechanisms.

Key Points: 
  • NORWALK, Conn., Oct. 3, 2023 /PRNewswire/ -- LifeSpan Vision Ventures today announced an investment in Deciduous Therapeutics, a pioneering longevity biotechnology company dedicated to enhancing human healthspan by developing innovative medicines targeting the elimination of senescent cells through restoring endogenous immune mechanisms.
  • Originating from the research lab of Dr. Anil Bhushan at the University of California, San Francisco (UCSF), Deciduous has made groundbreaking discoveries centered on Natural Killer T-cells (NKTs) as a potent endogenous immune mechanism capable of enabling senolysis.
  • Andrew Worden, Founding Partner of LifeSpan Vision Ventures, stated: "Our investment in Deciduous Therapeutics aligns with our mission to support companies dedicated to longevity and age-related disease therapeutics.
  • Deciduous Therapeutics is taking an innovative approach to senescence, initially targeting fibrotic and metabolic diseases, but their platform technology holds immense potential for various age-related conditions.

ARUP's New Institute for Research and Innovation in Diagnostic and Precision Medicine™ Will Forge the Future of Laboratory Medicine

Retrieved on: 
Friday, September 29, 2023
San Francisco, Laboratory, University, Clinical trial, CSO, ARUP Laboratories, University of California, San Francisco, COVID-19, Pathology, Stanford University, Research, Attention, History, SALT, Doctor of Philosophy, Translation, Harvard Medical School, ARUP, HERO, Stanford University School of Medicine, Leukemia, Tron Lightcycle Power Run, Patient, Machine learning, Physician, Lymphoma, Flow cytometry, Artificial intelligence, New institutional economics, Diagnosis, Growth, R, FDA, Medical device, Pharmaceutical industry, Medical imaging, MD

SALT LAKE CITY, Sept. 29, 2023 /PRNewswire/ -- ARUP Laboratories today announced the formation of the new ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ (R&I Institute).

Key Points: 
  • SALT LAKE CITY, Sept. 29, 2023 /PRNewswire/ -- ARUP Laboratories today announced the formation of the new ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ (R&I Institute).
  • The institute will improve the lives of patients by advancing groundbreaking diagnostic and prognostic technologies and innovative tests.
  • Now, with a broad vision as CSO and president of the Innovation Business Unit, her attention has turned to the R&I Institute.
  • "We've seen the need and the opportunity, and now we're here to fearlessly seek out the future of laboratory medicine."

Regel Therapeutics Awarded $1 Million from HS Chau Women in Enterprising Science Program at the Innovative Genomics Institute to Continue Developing Its Gene Modulation Technology

Retrieved on: 
Friday, September 29, 2023
San Francisco, Nobel Prize, CRISPR, Therapy, Nobel Prize in Chemistry, Biotechnology, University of California, San Francisco, Woman, Research, Gene expression, DSM-IV codes, HS, IGI, UC, Nobel, Entrepreneurship, Pharmaceutical industry, Medical device, Eduard August von Regel, Chemistry

The HS Chau WIES Program at the IGI is committed to addressing gender inequity in biotechnology and supporting entrepreneurs to develop innovative solutions for some of the world's greatest health problems.

Key Points: 
  • The HS Chau WIES Program at the IGI is committed to addressing gender inequity in biotechnology and supporting entrepreneurs to develop innovative solutions for some of the world's greatest health problems.
  • The IGI is working to advance revolutionary biotechnology that translates scientific breakthroughs into real-world solutions that are accessible and affordable.
  • With the generous philanthropic support of Solina Chau Hoi Shuen of Horizons Ventures, the IGI launched the WIES program to support and guide entrepreneurs who align with its mission.
  • Scientists selected for the program receive access to world-class resources to further their research using technologies such as CRISPR.

Orange Grove Bio Subsidiary Awarded $2.05 Million SBIR Phase II Grant to Advance Development of Novel Platelet Preservation Technology

Retrieved on: 
Thursday, September 28, 2023
Heart, Maintenance, Drug development, University, Therapy, AUC, Regeneron Pharmaceuticals, PNC Center, Harvard University, SBIR, Biotechnology, University of California, San Francisco, National Heart, Lung, and Blood Institute, Pathology, OGB, Refrigeration, Head, American Academy, Research, Temperature, Lung, PNC, Autoimmunity, Bangladesh Technical Education Board, Eli Lilly, National academy, Publishing, National Academy of Medicine, Lilly, Patient, UCSF, Risk, Immune system, Small Business Innovation Research, G04, Drug discovery, Science, Transforming protein RhoA, Immunology, Health, NIH, Technology transfer, Allen Institute, Pharmaceutical industry, Vaccine, MBBS

Preservation Bio seeks to transform blood banking for donated platelets with an ex vivo additive that protects platelets from the damage normally caused by refrigeration.

Key Points: 
  • Preservation Bio seeks to transform blood banking for donated platelets with an ex vivo additive that protects platelets from the damage normally caused by refrigeration.
  • The SBIR grant will help fund Preservation Bio’s continued advancement of G04 through preclinical development and toward the clinic.
  • With more than eight million platelet units donated yearly, the global platelet market is estimated to be at least $4 billion.
  • Orange Grove Bio fosters strong relationships with technology transfer offices outside of the traditional medical technology hubs of Boston and San Francisco.

NEW STUDY REVEALS THAT SOME CHILDREN WITH COMMON FORM OF ECZEMA SHOULD ALSO BE TESTED FOR ALLERGIC REACTIONS

Retrieved on: 
Tuesday, September 26, 2023
Allergy, Jiading District, Arm, University, Metal, Face, Skin care, JAK, University of California, San Francisco, Allergic contact dermatitis, Table tennis rubber, Journal of the American Academy of Dermatology, American Academy, Atopic dermatitis, Cosmetics, Inflammation, FAAD, Light, Journal, Nickel, Child, Immune system, Jeff, Steroid, Diagnosis, Hospital, Patient, Massachusetts General Hospital, Skin, Dietary supplement, Perfume, Dermatitis, Dermatology, MD

ROSEMONT, Ill., Sept. 26, 2023 /PRNewswire/ -- Eczema, which is a group of medical conditions that causes inflamed, irritated, and often itchy skin, affects millions of people worldwide. A new article published in the Journal of the American Academy of Dermatology reveals that children diagnosed with a type of eczema called atopic dermatitis – which they usually develop by 5 years of age – may also need to be tested for a second type of eczema called allergic contact dermatitis, which has similar symptoms and can be triggered by a range of substances that cause an allergic reaction.

Key Points: 
  • "It turns out that most of the things that I'm allergic to are very common ingredients in a lot of products," Schoeben said.
  • Poison ivy, poison oak and poison sumac are the most common causes of allergic reactions in the United States.
  • Other common causes of allergic contact dermatitis include metals (such as nickel), rubber, dyes, cosmetics, preservatives, and fragrances.
  • In these cases, the overall eczema may look very severe but once you remove the allergic component, the eczema seems much more manageable.

UCSF QBI, University College London, and Mount Sinai Identify Shared Molecular Mechanisms Across SARS-CoV-2 Variants that Allow Virus to Thrive Despite Vaccination

Retrieved on: 
Thursday, September 21, 2023
Vaccine, San Francisco, Infection, University College London, UCL, Cell Host & Microbe, Omicron, Senior, Life, HIV, Icahn School of Medicine at Mount Sinai, University, SARS-CoV-2, System, ORF6, COVID-19, Survival, University of California, San Francisco, Emerging Pathogens Institute, Viral, Research, Mount Sinai, Cell, Doctor of Philosophy, Delta, Assistant, Global Health, QBI, Genetics, Pandemic, G.H. Raisoni Department of Microbiology and Biotechnology, Quantitative Biosciences Institute, UC, UCSF, Laboratory, Pathology, SAN, CELL, School, Immune system, Gladstone Institutes, UCLA, Health, Adolfo, Virus, Pharmacy, Microbiology, Alpha

SAN FRANCISCO and LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- In a study published online in CELL today, scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers. In the paper titled, SARS-CoV-2 Variants Evolve Convergent Strategies to Remodel the Host Response, scientists carried out an unprecedented, systematic comparative study using the most infectious COVID-19 variants, namely Alpha, Beta, Gamma, Delta and Omicron to identify specific viral mutations responsible for hijacking a common host pathway, thereby leading to increased transmissibility, infectivity and survival. Specifically, they discovered a convergence in potent suppression of interferon-stimulated genes through several viral proteins, including Orf6 and Orf9b, which serve as innate immune antagonist proteins capable of blocking innate host immune response.

Key Points: 
  • The award, which included a $200,000 prize, is intended to provide support for his vision for progress against pandemic threats.
  • “Unfortunately, we continue to see new mutations and strains of SARS-CoV-2 despite innovations in new vaccines,” said Dr. Krogan, who founded the QBI Coronavirus Research Group (QCRG).
  • This finding is consistent with our investigation of early SARS-CoV-2 variants where certain viral proteins were highly expressed in infected cells which helped the virus infect our cells.
  • Their analysis pinpointed cellular pathways that are similarly modulated across variants during infection and represent putative targets for pan-coronavirus antivirals.

Rita and Alex Hillman Foundation Broadens Support for Nurse-Led Innovations that Improve End-of-Life Care

Retrieved on: 
Wednesday, September 20, 2023
Emory University, Prison, Partnership, CSE, Theology, Loneliness, University, Heart failure, Life, MSN, Arthur, Social support, Anxiety, COVID-19, Nursing, Health equity, Ageing, Candler School of Theology, University of California, San Francisco, Doctor of Philosophy, Arthur Vining Davis, Kidney disease, Grief, MD, Patient, Practitioner, Rita, Algorithm, RN, MSW, Boredom, BIPOC, Health literacy, Health administration, Caregiver, Breast cancer, Pharmaceutical industry

The $500,000 in grants, part of the Hillman Emergent Innovation: Serious Illness and End of Life (HSEI) program, will advance nursing-driven initiatives that radically improve care and narrow gaps in health equity.

Key Points: 
  • The $500,000 in grants, part of the Hillman Emergent Innovation: Serious Illness and End of Life (HSEI) program, will advance nursing-driven initiatives that radically improve care and narrow gaps in health equity.
  • “The quality of care delivered at the end of life is a bellwether for our society,” said Ahrin Mishan, Executive Director of The Rita and Alex Hillman Foundation.
  • The 2023 HSEI grant recipients are:
    The prison population is aging and the need for compassionate end-of-life care is great.
  • This community-based, nurse-led intervention will develop a culturally concordant, end-of-life doula model to increase social support and improved care for seriously ill LGBTQ+ patients.